MGC Pharmaceuticals (ASX:MXC) shared with investors its financial report for its most recent quarter.

As quoted in the press release:


Key Operational Highlights:

  • Multiple key milestones achieved for the Pharma operations including first materialprescription volumes issued, significant increase in patient numbers, and new revenue streams delivered
  • Patients in Australia and the United Kingdom being prescribed MGC Pharma’s phytocannabinoid based investigational medicines commenced in earnest during August, passing the 200, 400 and 800 prescription milestones within weeks during September and October – total prescriptions issued to date reached 1,000 at the end of October
  • Total cash receipts received for the September quarter of AU$413,000, with new Pharma revenue from recent sales of more than AU$400,000 to be received post quarter end

Roby Zomer, Co-founder and Managing Director of MGC Pharma, commented: “We have seen another period of excellent progress delivering on our ‘Seed to Medicine’ business strategy. We have achieved multiple milestones across our pharma business channels, the highlight being the continuing rapid growth of prescription numbers, doubling in just two weeks during September and continuing during October, which validates the quality and immediate patient demand for our phytocannabinoid based investigational medicinal products (IMP) and underpins our growth potential.

Click here to read the full press release.

Both locations expand access to the state’s widest-ranging inventory of medical cannabis products for Central Florida patients

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of two brand-new Central Florida dispensaries. The new Clearwater and Tampa locations mark the Company’s 81 st and 82 nd nationwide, respectively, widening patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the appointment of Bart Oates Esq., President of the NFL Alumni Association, to its Advisory Board.

Philip Young, CEO and Director of Lobe, stated, “We are honored to welcome Bart to our Advisory Board. His first-hand experience on and off the field are tremendously valuable as we continue our research involving mild traumatic brain injuries and PTSD. These issues are prevalent in contact sports and we believe that athletes will play a prominent role in the continued acceptance of psychedelic medicines as legitimate treatment. We look forward to working with Bart as we seek to forge long-term strategic relationships.”

Keep reading... Show less

HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that it has submitted its dossier to the United Kingdom’s Regulatory Food Safety Agency (the “FSA”).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210303005322/en/

Keep reading... Show less